Graham Capital Management L.P. Makes New Investment in Takeda Pharmaceutical Co. $TAK

Key Points

• Graham Capital Management L.P. acquired a new stake in Takeda Pharmaceutical Co., purchasing 158,760 shares valued at approximately $2.36 million in the first quarter.
• Takeda's stock recently opened at $14.99, with a market capitalization of $47.68 billion and a PE ratio of 49.95.
• Analyst ratings have been mixed, with Zacks Research lowering the stock's rating from "hold" to "strong sell," while the consensus rating remains at "hold."

Graham Capital Management L.P. purchased a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 158,760 shares of the company's stock, valued at approximately $2,361,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its position in shares of Takeda Pharmaceutical by 60.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 181,929 shares of the company's stock worth $2,409,000 after purchasing an additional 68,200 shares during the period. Northern Trust Corp lifted its stake in Takeda Pharmaceutical by 14.6% during the fourth quarter. Northern Trust Corp now owns 1,873,588 shares of the company's stock worth $24,806,000 after purchasing an additional 238,161 shares in the last quarter. Lido Advisors LLC acquired a new position in Takeda Pharmaceutical during the fourth quarter worth $364,000. Jane Street Group LLC boosted its position in shares of Takeda Pharmaceutical by 109.0% during the fourth quarter. Jane Street Group LLC now owns 254,647 shares of the company's stock worth $3,372,000 after buying an additional 132,817 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in shares of Takeda Pharmaceutical by 15,449.0% in the fourth quarter. BNP Paribas Financial Markets now owns 500,677 shares of the company's stock valued at $6,629,000 after buying an additional 497,457 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Zacks Research lowered Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a research note on Thursday, August 21st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Takeda Pharmaceutical presently has an average rating of "Hold".

Takeda Pharmaceutical Stock Up 0.7%

Shares of TAK traded up $0.11 during midday trading on Friday, hitting $15.40. The company had a trading volume of 3,326,096 shares, compared to its average volume of 2,558,513. Takeda Pharmaceutical Co. has a 1 year low of $12.80 and a 1 year high of $15.56. The firm has a market capitalization of $48.99 billion, a P/E ratio of 51.32 and a beta of 0.22. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.59 and a current ratio of 1.16. The company's 50-day simple moving average is $14.82 and its 200-day simple moving average is $14.77.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The firm had revenue of $7.45 billion for the quarter, compared to analysts' expectations of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, sell-side analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.